Immunosuppressive functions conferred by regulatory cytokines are important for maintaining homeostasis in immune responses. IL35 has recently emerged as a novel regulator of immune responses. Once thought to be specifically expressed by T regulatory cells, induction of IL35 expression has now been detected in multiple cell types in a variety of diseases, prompting research into regulation of its expression, signaling specificity, target cell populations, and functional outputs. Recent studies have revealed that by directing de novo generation of regulatory T and B cells and inhibiting T effector responses, IL35 plays an important role in the development of autoimmune diseases and cancer. IL35 is overexpressed in a variety of cancers and may exert its function both on antitumor immune responses as well as directly on tumor cells. As such, IL35 is rapidly emerging as a promising biomarker and an attractive cancer therapy target.
CITATION STYLE
Pylayeva-Gupta, Y. (2016). Molecular pathways: Interleukin-35 in autoimmunity and cancer. Clinical Cancer Research, 22(20), 4973–4978. https://doi.org/10.1158/1078-0432.CCR-16-0743
Mendeley helps you to discover research relevant for your work.